Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.46 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.46 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29825244 | 1.00 | MAPT (0.50) | MAPTMEN1KMT2AHIF1ACYP3A4 | |
| SCHEMBL29825232 | 0.84 | TP53 (0.41) | MAPTMEN1KMT2AHIF1ACYP3A4 | |
| SCHEMBL134961 | 0.84 | TP53 (0.41) | MAPTMEN1KMT2AHIF1ACYP3A4 | |
| SCHEMBL1560834 | 0.82 | KMT2A (0.43) | MAPTMEN1KMT2AHIF1ACYP3A4 | |
| SCHEMBL1154758 | 0.80 | IDO1 (0.50) | MAPTMEN1KMT2AHIF1ACYP3A4 | |
| SCHEMBL29493203 | 0.80 | IDO1 (0.50) | MAPTMEN1KMT2AHIF1ACYP3A4 | |
| SCHEMBL79525 | 0.79 | CA2 (0.44) | MAPTMEN1KMT2AHIF1ACYP3A4 | |
| SCHEMBL10451789 | 0.78 | MEN1 (0.43) | MAPTMEN1KMT2AHIF1ACYP3A4 | |
| SCHEMBL109397 | 0.78 | CA3 (0.48) | MEN1KMT2AIDO1MPOPSEN1 | |
| SCHEMBL92968 | 0.78 | CYP3A4 (0.48) | MAPTMEN1KMT2AHIF1ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3558298-B1 | ANTIDIABETIC SPIROCHROMAN COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12497382-B2 | GLP-1R modulating compounds | GILEAD SCIENCES, INC. (US) | 2025-12-16 | — | — | US | disclosed |
| CN-119874674-A | GLP-1R modulating compounds | 吉利德科学公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-114630823-B | GLP-1R Modulating Compounds | 吉利德科学公司 | 2025-01-28 | — | — | CN | disclosed |
| US-20240218021-A1 | CYCLIN INHIBITORS | CIRCLE PHARMA, INC. | 2024-07-04 | — | — | US | disclosed |
| CN-115461334-B | Benzimidazole derivative, and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2024-06-21 | — | — | CN | disclosed |
| WO-2024086814-A2 | CYCLIN INHIBITORS | CIRCLE PHARMA, INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| US-20230391747-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2023-12-07 | — | — | US | disclosed |
| US-11702404-B2 | GLP-1R modulating compounds | GILEAD SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702404-B2 | GLP-1R modulating compounds | GILEAD SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20020061853-A1 | Caspase inhibtors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2002-05-23 | — | — | US | disclosed |
| WO-2001090070-A2 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2001-11-29 | — | — | WO | disclosed |
| CN-1312783-A | Process for preparing fluorobenzyl derivatives | ASASHI GLASS CO (JP) | 2001-09-12 | — | — | CN | disclosed |
| EP-1114809-A1 | PROCESS FOR THE PREPARATION OF FLUOROBENZYL DERIVATIVES | Asahi Glass Co., Ltd. (JP) | 2001-07-11 | — | — | EP | disclosed |
| CN-1303380-A | Isothiazole derivatives as anticancer agents | PFIZER PROD INC (US) | 2001-07-11 | — | — | CN | disclosed |
| US-6245761-B1 | NERVOUS SYSTEM, CARDIOVASCULAR AND RESPIRATORY SYSTEM DISORDERS | ELI LILLY AND COMPANY | 2001-06-12 | — | — | US | disclosed |
| CN-1173867-A | Indolyl neuropeptide Y receptor antagonists | LILLY CO ELI (US) | 1998-02-18 | — | — | CN | disclosed |
| EP-0789688-A4 | INDOLYL NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 1997-11-19 | — | — | EP | disclosed |
| EP-0789688-A1 | INDOLYL NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1997-08-20 | — | — | EP | disclosed |
| WO-1997009308-A1 | INDOLYL NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1997-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702404-B2 | GLP-1R modulating compounds | GLP1R, GIPR, GPR119 | MAPT 3314/4885MEN1 1966/4885KMT2A 3870/4885 |
| US-20240218021-A1 | CYCLIN INHIBITORS | CCNI, CCNC, CDK2 | MAPT 3868/4885MEN1 1844/4885KMT2A 1479/4885 |
| US-20230391747-A1 | GLP-1R MODULATING COMPOUNDS | GLP1R, GIPR, GPR119 | MAPT 3314/4885MEN1 1966/4885KMT2A 3870/4885 |
| US-20020061853-A1 | Caspase inhibtors and uses thereof | CASP2, CASP1, CASP3 | MAPT 4765/4885MEN1 3413/4885KMT2A 3538/4885 |
| US-12497382-B2 | GLP-1R modulating compounds | GLP1R, GIPR, GPR119 | MAPT 3314/4885MEN1 1966/4885KMT2A 3870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.